Key Findings
The Global Post-Keytruda Oncology Market is projected to reach USD 62.0 Billion by 2032, up from USD 32.0 Billion in 2026, at a CAGR of 11.7% during forecast period 2026–2032.
Pembrolizumab loses key patent protection in major markets late this decade. Biosimilar entry will cut prices sharply in tendered European and Latin American systems. Originators are therefore shifting value towards newer formats and formulations.
PD-1 and VEGF bispecific antibodies attract the largest development spend. Several candidates originated with Chinese developers and were licensed to Western partners. None has completed a global phase three programme, so outcomes remain uncertain.
Subcutaneous formulations are a central defensive strategy for incumbent suppliers. A short injection replaces a longer intravenous infusion and frees infusion chair time. Payers weigh that convenience against any difference in acquisition cost.
Antibody-drug conjugates increasingly serve as combination partners rather than salvage options. Several approvals now pair a conjugate with a checkpoint inhibitor. Lung, breast and urothelial cancers lead this shift in clinical practice.
Asia Pacific supplies a growing share of the candidate pipeline. Chinese trials enrol quickly and generate early clinical data at lower cost. Western partners then run confirmatory global studies and handle regulatory filings.
Competition centres on trial evidence, tolerability, dosing convenience and price. Hospital pharmacy and procurement teams exert growing influence over formulary choice. Manufacturing scale matters most once biosimilar supply arrives.
Global Post-Keytruda Oncology Market Size and Forecast
The Global Post-Keytruda Oncology Market is estimated at USD 32.0 Billion in 2026 and is projected to reach USD 62.0 Billion by 2032. This represents a CAGR of 11.7% over the forecast period 2026-2032. Expansion rests on patent expiry on leading checkpoint inhibitors, bispecific antibody development, subcutaneous formulations, conjugate combinations, and biosimilar supply.
Hospitals, cancer centres, public tender bodies and insurers all shape demand in this field. Pricing pressure will pass through directly to the products tracked in the Checkpoint Inhibitor Oncology Drugs Market. Lung cancer remains the largest single indication by value.
Introduction
Post-Keytruda oncology covers the products positioned to take over from pembrolizumab as its market exclusivity ends. The category spans checkpoint inhibitor biosimilars, PD-1 and VEGF bispecific antibodies, subcutaneous formulations, conjugate backbones and newer immunotherapy agents.
The market spans originator companies, biosimilar manufacturers, licensing partners, hospital pharmacies and payers. Buyers include cancer centres, national tender bodies and private insurers. Development activity is concentrated in the PD-1/VEGF Bispecific Immuno-Oncology Market, where several candidates have entered global trials.
Future Outlook
By 2032, the Global Post-Keytruda Oncology Market is expected to witness substantial change rather than simple growth. Biosimilar entry, bispecific launches and subcutaneous conversion will all contribute. Cost per treated patient should fall in most markets.
Trial evidence, tolerability and price will separate the leading products. Delivery route will matter almost as much as molecule choice, as the Subcutaneous Immuno-Oncology Therapeutics Market already shows. Manufacturing scale and tender strategy will decide share through 2032.
Application Demand — Demand Intensity by Segment
Relative demand intensity across key application segments — each bar is labelled with its demand level.
Very High High Mod–High Moderate
Very High
Non-Small Cell Lung CancerHigh
Small Cell Lung CancerMod–High
Triple-Negative Breast CancerMod–High
Gastric and Oesophageal CancerModerate
Urothelial CarcinomaModerate
Melanoma and Skin Cancer Very High High Moderate–High Moderate
Regional Demand and Ecosystem Development Matrix
| Region | Market Maturity | Key Demand Driver | Dominant Application | Growth Outlook |
|---|
| North America | Mature | Largest checkpoint inhibitor spend and early biosimilar filings | PD-1/VEGF Bispecific Antibodies | Highest ↗ |
| Europe | Mature | Tendered procurement and rapid biosimilar substitution | PD-1 and PD-L1 Biosimilars | High |
| Asia Pacific | Developing | Chinese bispecific development and domestic PD-1 supply | PD-1/VEGF Bispecific Antibodies | Moderate–High |
| Latin America | Emerging | Public tenders favouring lower-cost biosimilars | PD-1 and PD-L1 Biosimilars | Moderate |
| Middle East and Africa | Emerging | New oncology centres and widening insurance cover | PD-1 and PD-L1 Biosimilars | Moderate |
Product Type and Performance Comparison Matrix
| Product Type | Primary Function | Performance Level | Value Share | Market Demand | Key Growth Factor |
|---|
| PD-1 and PD-L1 Biosimilars | Tendered Hospital Procurement | High | XXX | Rapidly Growing | Price resets the whole class |
| PD-1/VEGF Bispecific Antibodies | First-Line Lung and Breast Cancer Trials | Very High | XXX | Rapidly Growing | Largest share of development spend |
| Subcutaneous Checkpoint Inhibitor Formulations | Hospital Infusion and Day Units | High | XXX | High | Shorter administration frees chair time |
| Antibody-Drug Conjugate Backbones | Combination Regimens in Solid Tumours | High | XXX | High | Used increasingly as combination partners |
| mRNA and Other Novel Immunotherapy Agents | Investigational Combination Programmes | Moderate | XXX | Rapidly Growing | Mostly early clinical evidence |
| Cell Therapy and Tumour-Infiltrating Lymphocyte Options | Specialist Treatment Centres | Moderate | XXX | Moderate | Narrow eligibility and complex logistics |
Post-Keytruda Oncology Market Trends
Approaching Loss of Exclusivity
Key patents on the leading PD-1 inhibitor begin to lapse in major markets from 2028. Biosimilar developers in Korea, India and China have already built capacity in readiness. Originators are responding with new formulations, fixed-dose products and fresh indications.
PD-1 and VEGF Bispecific Antibodies
Dual blockade of PD-1 and the vascular endothelial growth factor pathway is the most watched approach. Chinese trials have reported progression-free survival gains against a checkpoint inhibitor alone. Global confirmatory studies are under way, and no such agent is yet approved outside China.
Conversion to Subcutaneous Delivery
Incumbent suppliers are moving infusion products to subcutaneous injection with a hyaluronidase enzyme. Treatment then takes minutes rather than most of an hour, which releases infusion capacity. Hospitals in Britain and the Nordic countries have adopted such switches quickly.
Conjugate and Checkpoint Combinations
Antibody-drug conjugates are increasingly tested alongside checkpoint inhibitors in first-line settings. Approved pairings already exist in urothelial carcinoma and in some breast cancer populations. Overlapping toxicity means dose and schedule work takes longer than for single agents.
Licensing from Chinese Developers
Western companies have paid large upfront sums for immuno-oncology assets originated in China. Completed early trials and lower development cost make these transactions attractive. Buyers accept the need to repeat key studies in other populations before filing.
Market Growth Drivers
Scale of the Existing Franchise
Pembrolizumab ranks among the largest selling medicines in the world across many indications. Any successor therefore addresses an unusually well-defined and well-funded market. Treatment pathways, diagnostics and prescriber familiarity are already firmly in place.
Clinical Need After Checkpoint Failure
Many patients progress after checkpoint inhibitor treatment and have limited remaining options. That population grows each year as first-line immunotherapy use widens further. New mechanisms are therefore tested in later lines before moving into earlier settings.
Biosimilar Cost Savings
Health systems expect large savings once checkpoint inhibitor biosimilars reach the market. Tendered procurement in Europe and Latin America accelerates substitution once approval arrives. Released budget can then fund newer and more expensive combination regimens.
Hospital Capacity Pressure
Infusion suites in many countries run close to capacity with long appointment waits. Shorter subcutaneous administration lets the same unit treat more patients each day. Service managers therefore support switching even when the drug cost is unchanged.
Capital Available for Oncology Deals
Large developers hold substantial cash and face pipeline gaps as older products mature. That combination has supported record upfront payments for immuno-oncology assets. Venture funding follows the same signals into earlier-stage research programmes.
Challenges in the Market
Unproven Bispecific Outcomes
Progression-free survival gains reported in single-country trials may not translate elsewhere. Overall survival data for several leading candidates remain immature or unpublished. Regulators outside China have asked for confirmatory evidence in broader populations.
Overlapping Toxicity in Combinations
Adding a conjugate or an antiangiogenic mechanism raises the burden of adverse events. Bleeding, proteinuria and interstitial lung disease all require careful monitoring in trials. Dose reductions can then dilute the benefit seen in earlier single-arm studies.
Pricing and Tender Pressure
Biosimilar entry will reset the reference price for the whole checkpoint inhibitor class. New products must then justify a premium against a much cheaper available comparator. Several national bodies already require survival benefit before granting any premium.
Manufacturing and Supply Transition
Subcutaneous products need different fill-finish lines, devices and cold chain handling. Enzyme co-formulation adds a supply dependency outside the originator company itself. Scaling bispecific antibody production also requires new purification capacity.
Scrutiny of Single-Country Data
Agencies have become more cautious about applications based on trials from one country. Additional multiregional studies add years and considerable cost to a programme. Sponsors must plan global enrolment early rather than retrofit it after the fact.
Competitive Landscape and Product Positioning
Leading Key Players — Relative Market Presence
Indicative relative presence based on strength of late-stage evidence, breadth of indications in development & readiness for biosimilar competition — market-share values masked as XXX
Merck & Co — XXX Summit Therapeutics — XXX BioNTech — XXX Pfizer — XXX AstraZeneca — XXX Others — XXX
Merck & Co
Rahway, United States
ProductSubcutaneous Checkpoint Inhibitor Formulations
TechnologyHyaluronidase Co-Formulation
End-userHospital Infusion and Day Units
American company whose subcutaneous pembrolizumab product uses a hyaluronidase variant developed by Alteogen of Korea.
Summit Therapeutics
Menlo Park, United States
ProductPD-1/VEGF Bispecific Antibodies
TechnologyDual PD-1 and VEGF Blockade
End-userLung Cancer Treatment Centres
American company that licensed the bispecific antibody ivonescimab from Akeso for North America, Europe and Japan.
ProductmRNA and Other Novel Immunotherapy Agents
TechnologymRNA Immunotherapy and Bispecific Design
End-userLung and Breast Cancer Centres
German company whose oncology pipeline spans mRNA immunotherapies and the bispecific antibody BNT327.
Pfizer
New York, United States
ProductPD-1/VEGF Bispecific Antibodies
TechnologyLicensed Bispecific Programmes
End-userOncology Treatment Centres
American company that licensed the PD-1 and VEGF bispecific antibody SSGJ-707 from 3SBio for markets outside China.
AstraZeneca
Cambridge, United Kingdom
ProductAntibody-Drug Conjugate Backbones
TechnologyTROP2-Directed Conjugate Chemistry
End-userBreast and Lung Cancer Centres
British company whose Datroway conjugate is developed and marketed jointly with Daiichi Sankyo of Japan.
Also covered: Akeso, Bristol Myers Squibb, Roche, Regeneron Pharmaceuticals, Sanofi, Celltrion, Samsung Bioepis, and other originator developers, biosimilar manufacturers, and licensing partners.
Post-Keytruda Oncology Market Segmentation
| Aspects | Details |
|---|
| By Type | - PD-1 and PD-L1 Biosimilars
- PD-1/VEGF Bispecific Antibodies
- Subcutaneous Checkpoint Inhibitor Formulations
- Antibody-Drug Conjugate Backbones
- mRNA and Other Novel Immunotherapy Agents
- Cell Therapy and Tumour-Infiltrating Lymphocyte Options
|
| By Route | - Intravenous Infusion
- Subcutaneous Injection
- Intratumoural Administration
- Autologous Cell Infusion
|
| By Line of Therapy | - First Line
- Second Line
- Later Lines
- Adjuvant and Neoadjuvant
|
| By End User | - Academic Cancer Centres
- Community Oncology Practices
- Public Tender Systems
- Private Insurers
|
Recent Developments
In September 2025, Merck & Co received United States approval for a subcutaneous pembrolizumab product administered by health care staff.
In September 2024, Summit Therapeutics presented the primary analysis of its HARMONi-2 trial of ivonescimab at the World Conference on Lung Cancer.
In June 2025, BioNTech entered a global partnership with Bristol Myers Squibb to co-develop the bispecific antibody BNT327.
In May 2025, Pfizer agreed an exclusive licence with 3SBio for the bispecific antibody SSGJ-707 in markets outside China.
In January 2025, AstraZeneca and Daiichi Sankyo received United States approval for Datroway in advanced hormone receptor-positive breast cancer.
This Market Report Will Answer the Following Questions
1
What is the global post-Keytruda oncology market size in 2026?
The global post-Keytruda oncology market is estimated at approximately $32.0 billion in 2026. Demand comes mainly from lung, head and neck, breast, gastric and urothelial cancer treatment. Melanoma and other skin cancers add smaller but steady volumes.
2
How large will the market be by 2032?
The global post-Keytruda oncology market is forecast to reach approximately $62.0 billion by 2032. This compares with about $32.0 billion in 2026, a CAGR of approximately 11.7%. Growth will come from bispecific antibody launches, subcutaneous conversion and conjugate combinations. Biosimilar supply will raise treated volumes while lowering price per patient.
3
What is driving growth in the market?
The scale of the existing checkpoint inhibitor franchise is the main driver. Clinical need after checkpoint failure, biosimilar savings, hospital capacity pressure and available deal capital also matter.
4
What are the key trends shaping the market?
Approaching loss of exclusivity is the clearest trend. PD-1 and VEGF bispecifics, subcutaneous delivery, conjugate pairings and licensing from Chinese developers are also reshaping the market.
5
Who are the leading companies in the global post-Keytruda oncology market?
Leading companies include Merck & Co, Summit Therapeutics, BioNTech, Pfizer and AstraZeneca. Other participants include Akeso, Bristol Myers Squibb, Roche, Regeneron Pharmaceuticals, Sanofi, Celltrion, Samsung Bioepis, and other originator developers, biosimilar manufacturers, and licensing partners. Competition centres on late-stage trial evidence, tolerability, dosing convenience, price per course, and manufacturing scale.